KR101158140B1 - Ｈｉｖ 감염 치료용 조합물 - Google Patents

Ｈｉｖ 감염 치료용 조합물 Download PDF

Info

Publication number
KR101158140B1
KR101158140B1 KR1020067019595A KR20067019595A KR101158140B1 KR 101158140 B1 KR101158140 B1 KR 101158140B1 KR 1020067019595 A KR1020067019595 A KR 1020067019595A KR 20067019595 A KR20067019595 A KR 20067019595A KR 101158140 B1 KR101158140 B1 KR 101158140B1
Authority
KR
South Korea
Prior art keywords
delete delete
hiv
aids
hiv infection
arc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067019595A
Other languages
English (en)
Korean (ko)
Other versions
KR20070011322A (ko
Inventor
핀-팽 린
베아타 노윅카-산스
그레고리 야마나카
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101158140(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20070011322A publication Critical patent/KR20070011322A/ko
Application granted granted Critical
Publication of KR101158140B1 publication Critical patent/KR101158140B1/ko
Assigned to 비브 헬스케어 유케이 (넘버4) 리미티드 reassignment 비브 헬스케어 유케이 (넘버4) 리미티드 권리의 전부이전등록 Assignors: 브리스톨-마이어스 스큅 컴퍼니
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020067019595A 2004-03-24 2005-03-01 Ｈｉｖ 감염 치료용 조합물 Expired - Lifetime KR101158140B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
US60/555,767 2004-03-24
PCT/US2005/006277 WO2005102392A2 (en) 2004-03-24 2005-03-01 Combinations for treating hiv infection

Publications (2)

Publication Number Publication Date
KR20070011322A KR20070011322A (ko) 2007-01-24
KR101158140B1 true KR101158140B1 (ko) 2012-06-19

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067019595A Expired - Lifetime KR101158140B1 (ko) 2004-03-24 2005-03-01 Ｈｉｖ 감염 치료용 조합물

Country Status (30)

Country Link
US (1) US7776863B2 (cg-RX-API-DMAC10.html)
EP (1) EP1732604B1 (cg-RX-API-DMAC10.html)
JP (1) JP4847441B2 (cg-RX-API-DMAC10.html)
KR (1) KR101158140B1 (cg-RX-API-DMAC10.html)
CN (1) CN1956720B (cg-RX-API-DMAC10.html)
AR (1) AR048333A1 (cg-RX-API-DMAC10.html)
AT (1) ATE474602T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005235116B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0509140A (cg-RX-API-DMAC10.html)
CA (1) CA2561146C (cg-RX-API-DMAC10.html)
CY (1) CY1111613T1 (cg-RX-API-DMAC10.html)
DE (1) DE602005022420D1 (cg-RX-API-DMAC10.html)
DK (1) DK1732604T3 (cg-RX-API-DMAC10.html)
ES (1) ES2347801T3 (cg-RX-API-DMAC10.html)
GE (1) GEP20104925B (cg-RX-API-DMAC10.html)
HR (1) HRP20100434T1 (cg-RX-API-DMAC10.html)
IL (1) IL178141A (cg-RX-API-DMAC10.html)
IN (1) IN2012DN06436A (cg-RX-API-DMAC10.html)
MY (1) MY144318A (cg-RX-API-DMAC10.html)
NO (1) NO337116B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ549778A (cg-RX-API-DMAC10.html)
PE (1) PE20060148A1 (cg-RX-API-DMAC10.html)
PL (1) PL1732604T3 (cg-RX-API-DMAC10.html)
PT (1) PT1732604E (cg-RX-API-DMAC10.html)
RU (1) RU2367439C2 (cg-RX-API-DMAC10.html)
SI (1) SI1732604T1 (cg-RX-API-DMAC10.html)
TW (1) TWI347184B (cg-RX-API-DMAC10.html)
UA (1) UA88463C2 (cg-RX-API-DMAC10.html)
WO (1) WO2005102392A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200607959B (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
WO2007049771A1 (ja) 2005-10-28 2007-05-03 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
JP5433691B2 (ja) * 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体
EP2303876B1 (en) * 2008-06-25 2014-03-19 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
US20110295365A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
EP2601174B1 (en) 2010-08-06 2014-11-26 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
US8912195B2 (en) 2010-12-02 2014-12-16 Bristol-Myers Squibb Company Alkyl amides as HIV attachment inhibitors
PT2670751E (pt) 2011-01-31 2015-07-29 Bristol Myers Squibb Co Métodos de fabrico de um composto profármaco inibidor da fixação do vih e intermediários
WO2012142080A1 (en) 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
EP2751119B1 (en) 2011-08-29 2016-11-23 VIIV Healthcare UK (No.5) Limited Fused bicyclic diamine derivatives as hiv attachment inhibitors
WO2013033059A1 (en) 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
WO2014025854A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Piperidine amide derivatives as hiv attachment inhibitors
ES2616432T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de alquenos tricíclicos como inhibidores de la unión del VIH
US9586957B2 (en) * 2013-03-27 2017-03-07 VIIV Healthcare UK (No.5) Limited 2-keto amide derivatives as HIV attachment inhibitors
WO2016210130A1 (en) * 2015-06-23 2016-12-29 Cytodyn Inc. Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014380A1 (en) * 2002-08-07 2004-02-19 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ506623A (en) * 1998-03-02 2002-10-25 Univ North Carolina Acylated betulin and dihydrobetulin derivatives, preparation thereof and use in treatment of retroviral infections
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
CA2469592C (en) * 2001-12-12 2005-08-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
CA2467718C (en) * 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014380A1 (en) * 2002-08-07 2004-02-19 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Also Published As

Publication number Publication date
CN1956720B (zh) 2010-12-15
MY144318A (en) 2011-08-29
IN2012DN06436A (cg-RX-API-DMAC10.html) 2015-10-09
JP4847441B2 (ja) 2011-12-28
ES2347801T3 (es) 2010-11-04
HK1096540A1 (en) 2007-06-01
AU2005235116A1 (en) 2005-11-03
NZ549778A (en) 2010-09-30
EP1732604A2 (en) 2006-12-20
ATE474602T1 (de) 2010-08-15
US7776863B2 (en) 2010-08-17
RU2367439C2 (ru) 2009-09-20
DK1732604T3 (da) 2010-11-15
NO337116B1 (no) 2016-01-25
TW200538117A (en) 2005-12-01
CA2561146C (en) 2013-12-24
KR20070011322A (ko) 2007-01-24
HRP20100434T1 (hr) 2010-09-30
IL178141A0 (en) 2006-12-31
US20050215545A1 (en) 2005-09-29
UA88463C2 (ru) 2009-10-26
GEP20104925B (en) 2010-03-25
AR048333A1 (es) 2006-04-19
NO20064547L (no) 2006-10-06
CA2561146A1 (en) 2005-11-03
DE602005022420D1 (de) 2010-09-02
SI1732604T1 (sl) 2010-10-29
ZA200607959B (en) 2008-06-25
WO2005102392A3 (en) 2006-07-20
BRPI0509140A (pt) 2007-09-04
PT1732604E (pt) 2010-09-24
JP2007530540A (ja) 2007-11-01
CN1956720A (zh) 2007-05-02
AU2005235116B2 (en) 2011-03-31
EP1732604B1 (en) 2010-07-21
TWI347184B (en) 2011-08-21
RU2006137555A (ru) 2008-04-27
PL1732604T3 (pl) 2010-12-31
CY1111613T1 (el) 2015-10-07
WO2005102392A2 (en) 2005-11-03
IL178141A (en) 2010-11-30
PE20060148A1 (es) 2006-03-04

Similar Documents

Publication Publication Date Title
US7776863B2 (en) Methods of treating HIV infection
US20050215544A1 (en) Methods of treating HIV infection
US20050215543A1 (en) Methods of treating HIV infection
De Clercq Emerging anti-HIV drugs
US20060058286A1 (en) Methods of treating HIV infection
ES2375788T3 (es) Sal de potasio de un inhibidor de integrasa de vih.
EP2646439B1 (en) Alkyl amides as hiv attachment inhibitors
EP2640720B1 (en) Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
US20070203147A1 (en) 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors
US20030069266A1 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
TWI222867B (en) Pharmaceutical compositions for treating hepatitis virus infections n-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds
US20190125875A1 (en) ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT
US7449476B2 (en) Tetrahydrocarboline antiviral agents
MX2012011415A (es) Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
HK1096540B (en) Methods of treating hiv infection
US10603321B2 (en) Small molecules targeting HIV-1 nef
US6225307B1 (en) Viral treatment
MXPA06010885A (es) Combinaciones para tratamiento de infeccion de virus de inmunodeficiencia humana (vih)
WO2026101812A1 (en) Hiv integrase inhibitors for treatment of hiv infection
WO2003041694A2 (en) Use of compounds comprising iodine, strontium and ascorbic acid as well as either bismuth, zinc or potassium in the treatment of aids
HK1056698B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20150519

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20160517

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20170330

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PC1801 Expiration of term

St.27 status event code: N-4-6-H10-H14-oth-PC1801

Not in force date: 20250302

Ip right cessation event data comment text: Termination Category : EXPIRATION_OF_DURATION